HomeArchive by category 'News' (Page 2)

News - News and Articles about commonly prescribed drugs

As soon as-Every day, Nebulized Bronchodilator Accredited for COPD Therapy

Posted in News on 11th November 2018

November 09, 2018

Yupelri is a long-acting muscarinic antagonist (LAMA)

Yupelri is a long-acting muscarinic antagonist (LAMA)

The Food and Drug Administration (FDA) has approved Yupelri (revefenacin; Theravance and Mylan) inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Yupelri is a long-acting muscarinic antagonist (LAMA); bronchodilation following inhalation of revefenacin is predominantly a site-specific effect. The product is intended for once-daily inhalation by a standard jet nebulizer connected to an air compressor. 

Yupelri was evaluated in 2 dose-ranging trials, 2 replicate 12-week, Phase 3 confirmatory trials, and a 52-week safety trial. In the 2 replicate 12-week, Phase 3 placebo-controlled trials (N=1229), patients aged ≥40 years with moderate to very severe COPD were randomized to receive Yupelri 175mcg once daily or placebo. The primary endpoint was change from baseline in trough FEV1 at day 85. 

Treatment with Yupelri showed significant improvement in lung function vs placebo. In Trial 1, the least square mean change in trough FEV1 was 127mL and -19mL in the Yupelri and placebo groups, respectively (treatment difference 146, 95% CI, 103.7, 188.8). In Trial 2, the least square mean change in trough FEV1 was 102mL and -45mL in the Yupelri and placebo groups, respectively (treatment difference 147, 95% CI, 97.0, 197.1). In addition, the peak FEV1 (within the first 2 hours after dosing) improvement on day 1 vs placebo was 133mL and 129mL in Trials 1 and 2, respectively. 

Related Articles

In Trial 1, the St. Georges Respiratory Questionnaire (SGRQ) responder rate (defined as an improvement in score of ≥4 as threshold) on day 85 was 49% for the Yupelri arm vs 34% for placebo (odds ratio [OR] 2.11, 95% CI 1.14, 3.92). In Trial 2, the SGRQ responder rate was 45% vs 39%, respectively (OR  1.31, 95% CI, 0.72, 2.38). 

The most common adverse events reported with therapy were cough, nasopharyngitis, upper respiratory tract infection, headache, and back pain. 

Yupelri will be available as 175mcg/3mL solution in unit-dose vials packaged in 30-count cartons. 

For more information call (877) 446-3679 or visit Mylan.com.

Scroll down to see the next article

Oral antibiotic reveals promise to remedy uncomplicated gonorrhea

Posted in News on 9th November 2018

An investigational oral antibiotic known as zoliflodacin was well-tolerated and efficiently cured most instances of uncomplicated gonorrhea when examined in a Part 2 multicenter medical trial, based on findings printed in the present day within the New England Journal of Medication. The Nationwide Institute of Allergy and Infectious Ailments (NIAID), a part of the U.S. Nationwide Institutes of Well being, sponsored the medical examine.

Gonorrhea is a standard sexually transmitted illness (STD) that impacts each women and men, significantly younger folks ages 15 to 24 years. Gonorrhea is the second mostly reported notifiable illness in america. In 2017, greater than 550,000 instances of gonorrhea had been reported in america. If untreated, gonorrhea an infection can result in pelvic inflammatory illness, ectopic being pregnant, infertility, and an elevated threat of HIV an infection. Pregnant ladies can cross the an infection to their infants, who can grow to be blind or develop life-threatening infections consequently.

Gonorrhea is brought on by the bacterium Nesseria gonorrhoeae, which has progressively developed resistance to every of the antimicrobials used to deal with it. In consequence, in 2015, the U.S. Facilities for Illness Management and Prevention revised gonorrhea remedy tips to advocate twin remedy with injectable ceftriaxone and oral azithromycin to cut back the emergence of resistance to ceftriaxone.

Zoliflodacin (previously generally known as ETX0914 and AZD0914), developed by Entasis Therapeutics based mostly in Waltham, Mass., represents a brand new sort of oral antibiotic that inhibits DNA synthesis another way than at present authorized antibiotics.

“The speed of reported gonorrhea instances in america has elevated 75 % because the historic low in 2009, and antibiotic resistance has significantly lowered the variety of remedy choices for this illness,” stated NIAID Director Anthony S. Fauci, M.D. “These encouraging analysis findings printed in the present day counsel that zoliflodacin has the potential to be a helpful and easy-to-administer oral antibiotic for treating gonorrhea.”

The examine occurred from November 2014 via December 2015 and was led by Stephanie N. Taylor, M.D., of Louisiana State College Well being Sciences Middle in New Orleans. Research investigators recruited sufferers from sexual well being clinics there and in Seattle; Indianapolis, Indiana; Birmingham, Alabama; and Durham, N.C. The trial enrolled 179 members (167 males and12 non-pregnant ladies) ages 18 to 55 years with both signs of uncomplicated urogenital gonorrhea, untreated urogenital gonorrhea or sexual contact with somebody with gonorrhea inside 14 days earlier than enrollment. Individuals had been randomly chosen to obtain both a single 2 or Three-gram dose of oral zoliflodacin or a 500-milligram (mg) dose of injectable ceftriaxone. Among the many 117 per-protocol members who had been evaluated six days after remedy, 98 % (48 of 49 members) of those that acquired the 2-gram zoliflodacin dose, 100 % (47 of 47 members) of those that acquired the Three-gram dose, and all (21 of 21) of the members within the ceftriaxone group had been thought-about cured of their urogenital gonorrhea based mostly on tradition outcomes.

Zoliflodacin cured all rectal gonorrheal infections (four of four members who acquired the 2-gram dose and 6 of 6 members who acquired the Three-gram dose) as did ceftriaxone (Three of three members). Nevertheless, the investigational drug didn’t fare as properly in treating sufferers with gonorrhea infections of the throat (pharyngeal): 67 % of volunteers who acquired the 2- gram dose (four of 6 members) and 78 % of those that acquired the Three-gram dose (7 of 9 members) had been cured. The entire members (four of four) within the ceftriaxone group achieved a remedy.

The investigational antibiotic was properly tolerated with transient gastrointestinal upset essentially the most generally reported adversarial impact. Microbiological analysis of post-treatment medical isolates didn’t display resistance to zoliflodacin.

In March 2018, NIAID accomplished a examine to judge zoliflodacin’s pharmacokinetics, security and tolerability as a single oral dose to function a bridge from the Part 2 medical trial formulation to the ultimate formulation for Part Three testing. Outcomes from that examine haven’t but been made public. Moreover, in September 2018 NIAID launched a Part 1 examine to judge the investigational drug’s cardiac results, an ordinary security check for brand new medication comparable to this.

Zoliflodacin has been awarded quick monitor standing by the U.S. Meals and Drug Administration for improvement as oral remedy for gonococcal infections. It’s anticipated to start Part Three testing within the Netherlands, South Africa, Thailand and america subsequent 12 months.



Researchers Establish Espresso Part That Might Present Neuroprotection

Posted in News on 9th November 2018
Dark roast coffee had higher levels of phenylindanes

Dark roast coffee had higher levels of phenylindanes

Certain compounds in coffee may have neuroprotective effects that could potentially reduce the risk for developing Alzheimer disease (AD) or Parkinson disease (PD), according to research out of the Krembil Brain Institute in Toronto, ON, Canada.

Specifically, the authors found that the compounds known as phenylindanes inhibited the aggregation of the amyloidgenic proteins beta-amyloid and tau, 2 proteins associated with AD and PD. In their study, the researchers observed that compared with light roast coffee, dark roast had higher levels of phenylindanes, and could potentially lead to a greater protective effect. “The caffeinated and decaffeinated dark roast both had identical potencies in our initial experimental tests,” said Dr Ross Mancini, a research fellow in medicinal chemistry. “So we observed early on that its protective effect could not be due to caffeine.”

While the authors acknowledge that a combination of factors may contribute to the neuroprotective effect associated with coffee consumption, they believe the identification of phenylindane as a dual-inhibitor of both beta-amyloid and tau is “noteworthy.”

“It’s the first time anybody’s investigated how phenylindanes interact with the proteins that are responsible for Alzheimer’s and Parkinson’s,” said Dr Mancini. “The next step would be to investigate how beneficial these compounds are, and whether they have the ability to enter the bloodstream, or cross the blood-brain barrier.”

Biogen and Eisai current detailed outcomes from section 1b examine of aducanumab at CTAD assembly

Posted in News on 8th November 2018

Biogen and Eisai Co., Ltd. introduced that Biogen introduced outcomes on the Medical Trials on Alzheimer’s Illness (CTAD) assembly, in Barcelona, Spain, from the current 36- and 48-month analyses of the continuing long-term extension (LTE) of the Section 1b examine of aducanumab, an investigational therapy for gentle cognitive impairment (MCI) as a consequence of Alzheimer’s illness (AD) and gentle AD.

A late-breaking oral presentation and a poster included knowledge from sufferers handled with aducanumab for as much as 36 and 48 months. Knowledge from each analyses confirmed a discount in amyloid plaque ranges in a dose- and time-dependent method, as measured by positron emission tomography (PET). As well as, analyses of exploratory medical endpoints, Medical Dementia Score Sum of Containers (CDR-SB) and the Mini-Psychological State Examination (MMSE), prompt a continued slowing of medical decline over 36 months and 48 months. The leads to every dosing arm had been usually according to beforehand reported analyses of this examine, and there have been no modifications to the risk-benefit profile of aducanumab.

“This Section 1b examine now has 4 years of aducanumab outcomes, and we’re inspired by these knowledge, which continued to indicate a discount in amyloid plaque ranges and counsel our investigational remedy might gradual medical development of the illness,” stated Alfred Sandrock, Jr., M.D., Ph.D., govt vp and chief medical officer at Biogen. “The Section three research are actually absolutely enrolled, and we stay pushed by the profound unmet wants of sufferers, households, caregivers and society.”​



Hypoglycemia Following Antifungal Tx in Affected person With Kind 1 Diabetes

Posted in News on 8th November 2018
Micafungin is a member of the echinocandin class of antifungal agents

Micafungin is a member of the echinocandin class of antifungal agents

A recent report published in The Journal of Clinical Endocrinology and Metabolism, describes the case of a patient with type 1 diabetes mellitus (T1DM) who developed hypoglycemia following antifungal therapy for a severe infection.

The 29-year-old female patient had a long history of uncontrolled T1DM and was diagnosed with cervical necrotizing fasciitis with mediastinal spread after presenting for evaluation of worsening dysphagia and dyspnea. Several debridement surgeries as well as broad spectrum antibiotics and antifungal therapy were required to treat her. At admission, she had an HbA1c of 13.4%; due to worsening infection, continuous tube feeds, and multiple surgeries, her insulin needs subsequently increased.

To provide broader antimicrobial coverage, micafungin, a member of the echinocandin class of antifungal agents, was initiated. After administration of micafungin, the patient’s insulin requirement dropped to 0 for more than 48 hours. Upon discontinuing micafungin and switching to a different antifungal, her insulin needs increased again.

“This is the first report of decreased insulin requirements in a patient with T1DM correlating with micafungin administration,” noted the authors. While the exact mechanism by which micafungin induces hypoglycemia has yet to be established, they hypothesized that the agent reduces blood glucose levels through inhibition of sodium-glucose transporter-1 (SGLT1) function.

Page 2 of 104:« 1 2 3 4 5 6 7 » Last »